About Vakaramoko "karam" Diaby
Dr. Diaby is currently the Track Director, Applied PharmacoEconomics for the UF Online Masters and an Assistant Professor of Pharmaceutical Outcomes and Policy, College of Pharmacy. Prior to joining UF, he was Assistant Professor of Health Economics and Outcomes Research in the Division of Economic, Social and Administrative Pharmacy, College of of Pharmacy and Pharmaceutical Sciences (COPPS) at Florida A&M University. Over the past 8 years, he has taught several courses targeting different audiences (Pharm D, Online Master’s, and Ph.D), graduated three Ph.D. students and 1 Master’s student. Since joining UF, Dr. Diaby has been advising 5 Ph.D students and 1 Masters’ student. He has served on 15 Masters and Ph.D committees [5 Matser’s (Chaired 3) and 10 Ph.D. (Chaired 5)]. Dr. Diaby has published over 40 peer-reviewed publications, including two book chapters. Dr. Diaby was the PI on a pilot project grant from the NIH/NIMHD, a Mitacs grant (Canada), and currently serves as a project-agnostic investigator on an NIH/NHGRI grant. Dr. Diaby recently completed a sub-award from a U54 center grant (U54OH011230) to study the impact of heat-related illness on the gross domestic product, agricultural and health sectors of the Southeastern and Coastal Center for Agricultural Health and Safety (SCCAHS)’ catchment area. He is the PI on a Nicklaus Children’s Hospital foundation pharmacogenomics grant and a Co-PI on an industry (Merck) contract. Dr. Diaby serves as a health economist on a HIV Telemedicine grant sponsored by the CDC. He has been contributing service to the College of Pharmacy by sitting on the curriculum and faculty governance committees. He is a grant peer-reviewer for three international agencies (UK, New Zealand and The Netherlands) and a peer-reviewer for several academic journals. Dr. Diaby was an academic editor for the journal PLOS ONE and currently serves on the editorial board of Pharmacoeconomics-Open.
Clinical Research AssociateSup Sante Paris – France
Health economics; Pharmacoeconomics; Comparative effectiveness research; Health disparities; Multi-Criteria Decision Analysis (MCDA); Policy evaluations
- Breast Cancers
- Health disparities and vulnerable populations
- Women’s Health